Ulrike Hoevelmann (Ulrike Hövelmann)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 11

Top Venues

Diabetes, obesity & metabolism

Diabetes care

Profil GmbH, Neuss

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Profil GmbH, Neuss

Germany

Scientific Study Advisor, MD :: Project Development

Publications

Ulrike Hoevelmann, Susanne Engberg, Tim Heise, Niels Rode Kristensen, Lea Nørgreen, Eric Zijlstra, Rasmus Ribel-Madsen
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes, obesity & metabolism 26 (5) (2024)
Ulrike Hoevelmann, Susanne Engberg, Tim Heise, Niels Rode Kristensen, Lea Nørgreen, Eric Zijlstra, Rasmus Ribel-Madsen
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes, obesity & metabolism (2024)
Ulrike Hoevelmann, Susanne Engberg, Tim Heise, Niels Rode Kristensen, Lea Nørgreen, Eric Zijlstra, Rasmus Ribel-Madsen
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes. Diabetes, obesity & metabolism 26 (5) (2024)
Simon R Heller, Tadej Battelino, Timothy S Bailey, Thomas R Pieber, Ulrike Hoevelmann, Leona Plum-Mörschel, Anita E Melgaard, Ronnie Aronson, Linda A DiMeglio, Thue Johansen, Thomas Danne
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes. Diabetes, obesity & metabolism (2023)
Simon R Heller, Tadej Battelino, Timothy S Bailey, Thomas R Pieber, Ulrike Hoevelmann, Leona Plum-Mörschel, Anita E Melgaard, Ronnie Aronson, Linda A DiMeglio, Thue Johansen, Thomas Danne
Integrated safety and efficacy analysis of dasiglucagon for treatment of severe hypoglycaemia in individuals with type 1 diabetes. Diabetes, obesity & metabolism (2023)
Thomas R Pieber, Ronnie Aronson, Ulrike Hoevelmann, Julie Willard, Leona Plum-Mörschel, Kim M Knudsen, Benedikte Bandak, Ramin Tehranchi
Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes care 44 (6) (2022)
Juris J Meier, Charlotte Granhall, Ulrike Hoevelmann, Andrea Navarria, Leona Plum-Moerschel, Chethana Ramesh, Andrea Tannapfel, Christoph Kapitza
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes. Diabetes, obesity & metabolism 24 (4) (2022)
Thomas R Pieber, Ronnie Aronson, Ulrike Hoevelmann, Julie Willard, Leona Plum-Mörschel, Kim M Knudsen, Benedikte Bandak, Ramin Tehranchi
Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes care (2021)
Ulrike Hoevelmann, Yaron Raiter, Anoop Chullikana, Mark Liu, Charles Donnelly, Tracey Lawrence, Nilanjan Sengupta, Gopu Cl, Gopinath Ranganna, Abhijit Barve
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study. Diabetes, obesity & metabolism 23 (12) (2021)
Ulrike Hoevelmann, Minna Braendholt Olsen, Ulrik Mouritzen, Daniela Lamers, Birgit Kronshage, Tim Heise
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. Diabetes, obesity & metabolism 21 (3) (2018)
Ulrike Hoevelmann, Britta Væver Bysted, Ulrik Mouritzen, Francesca Macchi, Daniela Lamers, Birgit Kronshage, Daniél Vega Møller, Tim Heise
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes care 41 (3) (2017)

Ulrike Hoevelmann.css-eqlu8i{font-size:small;padding-left:4px;} (Ulrike Hövelmann)

Publication Activity (10 Years)

Top Topics

Top Venues

Ulrike Hoevelmann (Ulrike Hövelmann)